MMAE

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
금요일, 4월 8, 2022
CD79B, DAR, EV, ADC, AACR, CDT, Research, Paul Scherrer Institute, Half-life, Therapeutic index, American Association, PSI, Senior, Entrepreneurship, Association, Technology, Control, Annual general meeting, American Association for Cancer Research, ETH Zurich, GLOBE, Animal, FDA, Translational research, MMAE, Fine chemical, Vaccine

We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody candidate.

Key Points: 
  • We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody candidate.
  • The poster number is 25 and will be presented by Isabella Attinger-Toller, Ph.D., Co-Founder, Senior VP of Translational Research.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.
  • Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

Retrieved on: 
금요일, 4월 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADCC, Cell, ALPP, ADCP, Section 32, Population, Inc., Phagocytosis, Trial of the century, EV, ADC, GLP, Brentuximab vedotin, Breast, AACR, Immunogenic cell death, Research, American Association, Neoplasm, Seagen, ALPPL2, U.S. Securities and Exchange Commission, NSCLC, Apoptosis, Senior, Security (finance), Association, American Association for Cancer Research, Safety, Intention, Control, Twitter, Stomach, Conjugation, Cervical cancer, SGN, Urinary bladder, Union, Toxicity, Immortalised cell line, Protein, Patient, MMAE, Enfortumab vedotin, Large-cell lung carcinoma, Induced cell cycle arrest, Fine chemical, Pharmaceutical industry, Vaccine, NMIBC, B7-H4

These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, April 8-13, 2022.

Key Points: 
  • These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, April 8-13, 2022.
  • Seagen and Astellas Pharma Inc. are co-developing enfortumab vedotin under a 50:50 worldwide development and commercialization collaboration.
  • Additionally, preclinical data presented from SGN-ALPV suggest it may have applications across several tumor types and adds to our broad pipeline of novel ADCs.
  • Enfortumab vedotin demonstrated antitumor activity in preclinical models of non-muscle invasive bladder cancer (NMIBC).

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
목요일, 3월 17, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CAPAC, Plasma, Human, Therapy, Trial of the century, AACR, American Association, Neoplasm, Cancer, Doxorubicin, CEO, Association, Safety, American Association for Cancer Research, Patient, MMAE, Toxicity, Pharmaceutical industry, Medical imaging, CAPAC and SQ3370, Shasqi, CAPAC AND SQ3370, SHASQI

Weve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor.

Key Points: 
  • Weve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor.
  • It utilizes Shasqis proprietary CAPAC platform, an approach that activates cancer drugs at a tumor with decreased systemic toxicity.
  • Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the tumor site.
  • Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies.

ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer

Retrieved on: 
화요일, 3월 8, 2022
Genetics, Safety, Molecular biology, MMAE, AACR, LDS, University of Texas Southwestern Medical Center, American Association for Cancer Research, University, Drug development, Daiichi Sankyo, Therapy, DARS, Cancer, Non-Hodgkin lymphoma, Lymphoma, PD, Celgene, Peking University, Rockefeller University, Mab, Merck, CD70, National university, Ovarian cancer, RATS, Trastuzumab, Therapeutic index, Doctor of Philosophy, LD, Patient, Renal cell carcinoma, American Association, Technology, Biology, Drug discovery, Benchmarking, Control, PK, Association, HER2, ADC, NSCLC, Fine chemical, Pharmaceutical industry, Vaccine, Pharmacology, Biochemistry

"These presentations at the AACR annual meeting will demonstrate the continued and rapid advancement of our lead programs as well as the potential of our ADC technology.

Key Points: 
  • "These presentations at the AACR annual meeting will demonstrate the continued and rapid advancement of our lead programs as well as the potential of our ADC technology.
  • I look forward to bringing these programs to clinical trials to help patients with cancer."
  • ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
  • Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages.

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer

Retrieved on: 
화요일, 1월 25, 2022
People, National Cancer Institute, Government of Canada, Survival, American Society of Clinical Oncology, Trial of the century, Patient, MMAE, Squamous cell carcinoma, Man, Transitional epithelium, Apoptosis, Union, General manager, Bladder cancer, Metastasis, Veni, vidi, vici, Disease, Society, Brentuximab vedotin, Cancer, Seagen, Recurrence, EV, Tissue, Occupation, Risk factor, Smoking, Princess Margaret Cancer Centre, Prognosis, O'Donnell dynasty, ADC, Diagnosis, Quality of life, Pivotal trial, Induced cell cycle arrest, Risk, Transitional cell carcinoma, Twitter, Professor, Cell, Platinum, Enfortumab vedotin, Medical imaging, Dietary supplement, Pharmaceutical industry, Immunotherapy, MD

A recent Seagen Canada survey gauging Canadian's knowledge of bladder cancer, conducted by Leger Research, found that many Canadians have limited knowledge as it relates to the condition.

Key Points: 
  • A recent Seagen Canada survey gauging Canadian's knowledge of bladder cancer, conducted by Leger Research, found that many Canadians have limited knowledge as it relates to the condition.
  • "Seagen is proud of our transformative scientific discoveries that continue to address and support those who live with cancer," says Sandra Heller, General Manager of Seagen Canada Inc. "PADCEV represents our dedication to improving the lives of patients through innovative targeted therapies."
  • Bladder Cancer.
  • Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer.

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

Retrieved on: 
월요일, 12월 20, 2021
CD166, Twitter, B-cell lymphoma, Clinical trial, Nausea, Therapy, ADC, AbbVie, Head, Trae tha Truth, LinkedIn, Breast cancer, CD71, HIV disease progression rates, Cleavage, COVID-19, Fatigue, Safety, Research, Risk, Bristol Myers Squibb, United, Platinum, Webcast, Anemia, Adenocarcinoma, Cancer, Patient, DAR, MMAE, Pharmaceutical industry, HNSCC

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced preliminary Phase 2 results in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC), who were treated with CX-2029 – a CD71-directed conditionally activated antibody-drug conjugate (ADC) being co-developed by CytomX and AbbVie.

Key Points: 
  • The median number of prior therapies in the metastatic setting was two (range, 1-5) for sqNSCLC and three (range, 1-9) for HNSCC.
  • The safety profile was consistent with previous Phase 1 observations, with no new safety signals identified.
  • Thirteen patients, eight with sqNSCLC and five with HNSCC, were still on treatment as of the data cut off.
  • CytomX management will host a conference call and a simultaneous webcast today at 5 p.m.

Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting

Retrieved on: 
화요일, 11월 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADC, SITC, HNSCC, Inc., Breast, Immunogenic cell death, Society, Cancer, 2021 Essex County Council election, Program, Phagocytosis, Society for Immunotherapy of Cancer, Neoplasm, Annual general meeting, Large-cell lung carcinoma, Antibody, ADCP, Therapy, Control, NSCLC, Abstract, ADCC, Immunotherapy, MMAE, Head, SGN, Patient, Vaccine

Each program combines antibodies targeted to an immune checkpoint [PD-(L)1 or B7-H4] with the cytotoxic properties of the vedotin payload.

Key Points: 
  • Each program combines antibodies targeted to an immune checkpoint [PD-(L)1 or B7-H4] with the cytotoxic properties of the vedotin payload.
  • We are excited to advance two novel immune checkpoint vedotin ADCs, SGN-PDL1V and SGN-B7H4V, into phase 1 studies.
  • (Abstract #854)
    The abstracts published in advance of the SITC Annual Meeting can be found here .
  • Details of Seagen Presentations at SITC Annual Meeting 2021:

Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

Retrieved on: 
목요일, 10월 7, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Infrared spectroscopy correlation table, Therapy, Ovarian cancer, Biotechnology, Intention, Drug development, Bachelor of Medicine, Bachelor of Surgery, Cancer, Webcast, Pneumonitis, SEC, Neutropenia, Center, AACR, Technology, Squamous cell carcinoma, Conference, COVID-19, Investor, Grade 3, U.S. Securities and Exchange Commission, Thromboxane A2, Toxic leukoencephalopathy, Neoplasm, Clinical trial, MRCP, DLT, NASDAQ, IHC, Bicycle, Tumor lysis syndrome, Phase, MMAE, Brentuximab vedotin, Review, Coagulopathy, Kidney, Private Securities Litigation Reform Act, Forward-looking statement, Risk, RECIST, Orange Riots, ADC, Security (finance), Neck, Breast, Patient, Anemia, Head, MT1-MMP, BTC, Pharmaceutical industry, Vaccine

We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.

Key Points: 
  • We look forward to providing additional clinical data on BT5528 and BT8009 next year, and initiating our Phase I/II study for BT7480 later this year.
  • BT5528, a BTC targeting EphA2, a target for which prior antibody-based approaches have been unsuccessful, has demonstrated preliminary anti-tumor activity.
  • Doses of BT5528 administered to date have been tolerated in the ongoing Phase I portion of the Phase I/II trial.
  • ET to review the BT5528 trial data being presented at the AACR-NCI-EORTC meeting and provide an update on preliminary findings from the BT8009 trial.

Global Ovarian Cancer Pipeline Market Report 2021: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
화요일, 10월 5, 2021
Women, Health, Oncology, Asparagine, News, Clinical trial, Neoplasm, Mergers and acquisitions, II, Ovarian cancer, Atezolizumab, Therapy, III, Alanine, Acquisition, TF, PD-1, Ligand, Pembrolizumab, PD-L2, Human, PD-L1, ADC, Cell, MMAE, Organic acid, Discovery, Birth control, Pharmaceutical industry, Vaccine

This "Ovarian cancer - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian cancer pipeline landscape.

Key Points: 
  • This "Ovarian cancer - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian cancer R&D.
  • This segment of the Ovarian cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ovarian cancer drugs.

Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

Retrieved on: 
일요일, 9월 19, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cohort, Cervical cancer, European Society for Medical Oncology, Bleeding, ADC, Union, Cell, Safety, ESMO, Inc., Progression-free survival, MMAE, National Cancer Institute, SEC, Vaccine, Network, U.S. Securities and Exchange Commission, Annual general meeting, Twitter, Ovarian cancer, Technology, Survival, Incidence, PFS, Media release, Clinical trial, Oncology, Patient, Annual report, Therapy, European Society of Gynaecological Oncology, Cancer, Woman, ORR, Risk, HIV disease progression rates, Peripheral neuropathy, Security (finance), Intention, Environment, Antibody, European Union, Risk management, HPV, Bevacizumab, Pembrolizumab, Nasdaq, Metastasis, Pharmaceutical industry, Medical imaging, Birth control, Road, Mineral wool, Fuel oil, Fused quartz, Cervical Cancer, the innovaTV 205 Trial, Tisotumab Vedotin, Seagen, Genmab, the Seagen and Genmab Collaboration, CERVICAL CANCER, THE INNOVATV 205 TRIAL, TISOTUMAB VEDOTIN, SEAGEN, GENMAB, THE SEAGEN AND GENMAB COLLABORATION

Interim results from the innovaTV 205 study show the potential for tisotumab vedotin to treat these patients with encouraging response rates in combination with carboplatin and also in combination with pembrolizumab.

Key Points: 
  • Interim results from the innovaTV 205 study show the potential for tisotumab vedotin to treat these patients with encouraging response rates in combination with carboplatin and also in combination with pembrolizumab.
  • Based on these results from the innovaTV 205 study, we also plan to evaluate tisotumab vedotin further in various combinations in first-line metastatic or recurrent cervical cancer.
  • We recognize the need for new therapies for patients with cervical cancer globally and are committed to advancing the tisotumab vedotin development program.
  • Additionally, Seagen and Genmab presented data from dose-escalation cohorts of the innovaTV 205 study at the 2021 International Gynecologic Cancer Society (IGCS) Annual Meeting held August 30-September 2, 2021.